Corvus Pharmaceuticals director David Scott Moore acquired 21,700 common shares through an option exercise on June 11, 2026, according to an SEC filing. The transaction was valued at approximately $250,236 based on a weighted average purchase price of $11.53 per share. Following the purchase, Moore directly holds 21,700 shares worth about $252,000 at the June 11 closing price of $11.60, representing less than 0.03% of the company. He also received 15,000 stock options with an exercise price of $11.60 that vest in about a year. Corvus Pharmaceuticals, a clinical-stage immuno-oncology company, has seen its stock price rise 217% over the past year, with a market capitalization of $1.07 billion as of June 22, 2026.
Corvus Pharmaceuticals IncDirector's insider purchase signals confidence in the company's prospects.